JP2021504385A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504385A5 JP2021504385A5 JP2020529160A JP2020529160A JP2021504385A5 JP 2021504385 A5 JP2021504385 A5 JP 2021504385A5 JP 2020529160 A JP2020529160 A JP 2020529160A JP 2020529160 A JP2020529160 A JP 2020529160A JP 2021504385 A5 JP2021504385 A5 JP 2021504385A5
- Authority
- JP
- Japan
- Prior art keywords
- thromboxane
- cancer
- pharmaceutical composition
- receptor antagonist
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229940123987 Thromboxane A2 receptor antagonist Drugs 0.000 claims description 25
- 239000003769 thromboxane A2 receptor blocking agent Substances 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 23
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 206010027476 Metastases Diseases 0.000 claims description 12
- 230000009401 metastasis Effects 0.000 claims description 12
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims description 6
- -1 Rinotoroban Chemical compound 0.000 claims description 6
- 229940122202 Thromboxane receptor antagonist Drugs 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 239000002396 thromboxane receptor blocking agent Substances 0.000 claims description 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 229950004274 ifetroban Drugs 0.000 claims description 4
- BBPRUNPUJIUXSE-DXKRWKNPSA-N ifetroban Chemical compound CCCCCNC(=O)C1=COC([C@H]2[C@H]([C@@H]3CC[C@H]2O3)CC=2C(=CC=CC=2)CCC(O)=O)=N1 BBPRUNPUJIUXSE-DXKRWKNPSA-N 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 102000003938 Thromboxane Receptors Human genes 0.000 claims description 3
- 108090000300 Thromboxane Receptors Proteins 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- IOFUFYLETVNNRF-OSAZKUMMSA-N (1R,2R,5S)-AH23848 Chemical compound N1([C@H]2C(=O)C[C@@H]([C@@H]2CC\C=C/CCC(=O)O)OCC=2C=CC(=CC=2)C=2C=CC=CC=2)CCOCC1 IOFUFYLETVNNRF-OSAZKUMMSA-N 0.000 claims description 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 2
- WHUIENZXNGAHQI-BNGKFCBFSA-N (e)-6-[(2s,4s,5r)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]hex-4-enoic acid Chemical compound C1([C@H]2O[C@H](OC[C@H]2C/C=C/CCC(=O)O)C=2C(=CC=CC=2)Cl)=CC=CC=C1O WHUIENZXNGAHQI-BNGKFCBFSA-N 0.000 claims description 2
- SXHUZJPIRVLMHY-AZPSIHDESA-N (z)-7-[(1r,3s,4s,5s)-3-[[(2r)-2-cyclopentyl-2-hydroxyacetyl]amino]-6,6-dimethyl-4-bicyclo[3.1.1]heptanyl]hept-5-enoic acid Chemical compound C1([C@@H](O)C(=O)N[C@@H]2[C@@H](C\C=C/CCCC(O)=O)[C@@H]3C[C@H](C2)C3(C)C)CCCC1 SXHUZJPIRVLMHY-AZPSIHDESA-N 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical compound N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 102000003800 Selectins Human genes 0.000 claims description 2
- 108090000184 Selectins Proteins 0.000 claims description 2
- 206010043515 Throat cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 125000000304 alkynyl group Chemical group 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 239000013059 antihormonal agent Substances 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 201000006974 gastroesophageal cancer Diseases 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims description 2
- 229950004496 ramatroban Drugs 0.000 claims description 2
- WVVUYAHTYLRPEB-UHFFFAOYSA-M sodium;2-[4-[[1-[[(4-chlorophenyl)sulfonylamino]methyl]cyclopentyl]methyl]phenyl]acetate Chemical compound [Na+].C1=CC(CC(=O)[O-])=CC=C1CC1(CNS(=O)(=O)C=2C=CC(Cl)=CC=2)CCCC1 WVVUYAHTYLRPEB-UHFFFAOYSA-M 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 230000007755 survival signaling Effects 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- XOKSLPVRUOBDEW-UHFFFAOYSA-N pinane Chemical compound CC1CCC2C(C)(C)C1C2 XOKSLPVRUOBDEW-UHFFFAOYSA-N 0.000 claims 2
- IULOBWFWYDMECP-UHFFFAOYSA-N 2-[4-[2-[(4-chlorophenyl)sulfonylamino]ethyl]phenyl]acetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1CCNS(=O)(=O)C1=CC=C(Cl)C=C1 IULOBWFWYDMECP-UHFFFAOYSA-N 0.000 claims 1
- HWEOXFSBSQIWSY-MRXNPFEDSA-N 3-[(6r)-6-[(4-chlorophenyl)sulfonylamino]-2-methyl-5,6,7,8-tetrahydronaphthalen-1-yl]propanoic acid Chemical compound N([C@H]1CC2=CC=C(C(=C2CC1)CCC(O)=O)C)S(=O)(=O)C1=CC=C(Cl)C=C1 HWEOXFSBSQIWSY-MRXNPFEDSA-N 0.000 claims 1
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N Seratrodast Chemical compound O=C1C(C)=C(C)C(=O)C(C(CCCCCC(O)=O)C=2C=CC=CC=2)=C1C ZBVKEHDGYSLCCC-UHFFFAOYSA-N 0.000 claims 1
- 229950008150 daltroban Drugs 0.000 claims 1
- 229930006728 pinane Natural products 0.000 claims 1
- 229960003090 seratrodast Drugs 0.000 claims 1
- 229950001286 terutroban Drugs 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002022 anti-cellular effect Effects 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592365P | 2017-11-29 | 2017-11-29 | |
| US62/592,365 | 2017-11-29 | ||
| PCT/US2018/062967 WO2019108736A1 (en) | 2017-11-29 | 2018-11-29 | Methods of inhibiting tumor metastasis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021504385A JP2021504385A (ja) | 2021-02-15 |
| JP2021504385A5 true JP2021504385A5 (https=) | 2022-01-06 |
| JP7305197B2 JP7305197B2 (ja) | 2023-07-10 |
Family
ID=66664589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529160A Active JP7305197B2 (ja) | 2017-11-29 | 2018-11-29 | 腫瘍転移を阻害する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US11471444B2 (https=) |
| EP (1) | EP3716973A4 (https=) |
| JP (1) | JP7305197B2 (https=) |
| KR (1) | KR102687556B1 (https=) |
| CN (2) | CN111432817B (https=) |
| AU (1) | AU2018375378A1 (https=) |
| CA (1) | CA3082839A1 (https=) |
| TW (1) | TW201924719A (https=) |
| WO (1) | WO2019108736A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220164000A (ko) * | 2020-03-31 | 2022-12-12 | 어플라이드 메디칼 테크놀로지스 엘엘씨 | Pgd2/dp2 및 트롬복산 a2/tp 수용체의 이중 길항제 및 이상 면역 반응 또는 혈전성 체질의 치료를 위한 이의 용도 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5066480A (en) | 1988-04-11 | 1991-11-19 | E. R. Squibb & Sons, Inc. | Method of preventing or reducing adverse reactions to protamine using a thromboxane a2 receptor antagonist |
| US4839384A (en) | 1988-10-07 | 1989-06-13 | E. R. Squibb & Sons, Inc. | Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist |
| US5153327A (en) | 1988-12-23 | 1992-10-06 | E. R. Squibb & Sons, Inc. | 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| US5100889A (en) | 1989-04-03 | 1992-03-31 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| ZA911453B (en) | 1990-03-19 | 1991-11-27 | Squibb & Sons Inc | Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromoboxane,a2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation |
| US5158967A (en) * | 1991-06-12 | 1992-10-27 | E. R. Squibb & Sons, Inc. | 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease |
| US5281716A (en) * | 1992-06-18 | 1994-01-25 | Bristol-Myers Squibb Company | Method for preparing 7-oxabicycloheptyl substituted oxazole amide prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds |
| US5260449A (en) | 1992-08-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Method for preparing 7-oxabicycloheptyl substituted bromooxazole amide prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds |
| US5399725A (en) | 1993-05-27 | 1995-03-21 | Bristol-Myers Squibb Co. | 7-oxabicycloheptane carboxylic acid prostaglandin analog intermediates useful in the preparation of anti-thrombotic and anti-vasospastic compounds and method for preparing same |
| US5332840A (en) | 1993-05-27 | 1994-07-26 | Bristol-Myers Squibb Company | Method for preparing a benzaldehyde intermediate |
| US5605917A (en) | 1994-12-22 | 1997-02-25 | Bristol-Myers Squibb Company | Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog |
| IL137937A0 (en) | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
| AU2001264729A1 (en) * | 2000-05-22 | 2001-12-03 | Nitromed, Inc. | Thromboxane inhibitors, compositions and methods of use related applications |
| KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| EP1986675A2 (en) | 2006-02-24 | 2008-11-05 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Extracellular matrix/metastasis modifer genes for the prevention or inhibition of metastasis or growth of tumor and for characterization of tumor |
| US20080160024A1 (en) | 2006-12-07 | 2008-07-03 | Board Of Trustees Of The University Of Arkansas | Inhibition of cancer metastasis |
| WO2009089098A1 (en) | 2008-01-03 | 2009-07-16 | Musc Foundation For Research Development | Methods for the treatment of cancers |
| US9283266B2 (en) | 2008-02-28 | 2016-03-15 | University Of Notre Dame | Metastasis inhibition preparations and methods |
| US8912167B2 (en) | 2011-05-19 | 2014-12-16 | Eugene J. Oliva | Heparin-based compositions and methods for the inhibition of metastasis |
| US20170226514A1 (en) | 2014-08-13 | 2017-08-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Prevention of tumour metastasis by inhibition of necroptosis |
-
2018
- 2018-11-29 KR KR1020207017233A patent/KR102687556B1/ko active Active
- 2018-11-29 WO PCT/US2018/062967 patent/WO2019108736A1/en not_active Ceased
- 2018-11-29 EP EP18884156.3A patent/EP3716973A4/en active Pending
- 2018-11-29 TW TW107142806A patent/TW201924719A/zh unknown
- 2018-11-29 CN CN201880077049.3A patent/CN111432817B/zh active Active
- 2018-11-29 US US16/767,534 patent/US11471444B2/en active Active
- 2018-11-29 CA CA3082839A patent/CA3082839A1/en active Pending
- 2018-11-29 JP JP2020529160A patent/JP7305197B2/ja active Active
- 2018-11-29 CN CN202311091198.4A patent/CN117122687A/zh active Pending
- 2018-11-29 AU AU2018375378A patent/AU2018375378A1/en not_active Abandoned
-
2022
- 2022-09-09 US US17/941,371 patent/US20230090578A1/en not_active Abandoned
-
2023
- 2023-08-11 US US18/448,495 patent/US20240041839A1/en not_active Abandoned
-
2024
- 2024-11-18 US US18/951,228 patent/US20250144079A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7190549B2 (ja) | Ｈｄａｃ阻害剤とｐｄ－１阻害剤との組み合わせ療法 | |
| ES2660263T5 (en) | Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments | |
| JP5826961B2 (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン塩類 | |
| KR102279999B1 (ko) | 선택적 에스트로겐 수용체 분해제로서의 벤조티오펜 유도체 및 그의 조성물 | |
| JP6568093B2 (ja) | ガンの処置に有用なｔｉｅ２キナーゼの阻害方法 | |
| US20210353596A1 (en) | Combination treatment of cancer | |
| JP2024521706A5 (https=) | ||
| JP6956725B2 (ja) | 抗増殖化合物、ならびにそれらの薬学的組成物及び使用 | |
| KR20190022520A (ko) | Hdac 억제제 및 pd-l1 억제제의 병용 요법 | |
| CN102740851A (zh) | Pi3k抑制剂和mek抑制剂的组合 | |
| JP2015520143A5 (https=) | ||
| JP2023500396A (ja) | ツカレソール誘導体及びその使用 | |
| JP2018512403A (ja) | 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用 | |
| TW201138764A (en) | Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents | |
| TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
| JP2024147816A (ja) | がん治療における免疫モジュレーションのための組合せ | |
| JP2022169780A (ja) | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 | |
| TW202313559A (zh) | 組蛋白去乙醯化酶6和熱休克蛋白90之雙重抑制劑 | |
| TW201806592A (zh) | 治療癌症的方法 | |
| JP2021504385A5 (https=) | ||
| JP2023505687A (ja) | 癌の処置方法 | |
| JPWO2019177011A1 (ja) | 腫瘍免疫賦活剤 | |
| JP2024516037A5 (https=) | ||
| CN110891944A (zh) | 用于治疗癌症的化合物、组合物及其用途 | |
| CN113993515B (zh) | 使用藏红花酸治疗实体肿瘤的方法 |